Retatrutide vs Semaglutide: Research Peptide Comparison
Retatrutide and semaglutide are two of the most discussed metabolic research peptides in current literature. This comparison summarises how investigators describe each compound, what receptor targets they act on in published studies, and how Amino Fuel Labs documents identity and purity for both. All material on this page is research peptide information for laboratory research only and is not for human consumption.
Receptor profile in published literature
Semaglutide is described in published literature as a selective GLP-1 receptor agonist with an extended half-life suitable for once-weekly study protocols. Retatrutide is described as a triple agonist that engages GLP-1, GIP, and glucagon receptors. Researchers comparing the two in metabolic models therefore note a broader pharmacology for retatrutide, while semaglutide retains a single-receptor profile that simplifies study design. This page does not state that either compound treats, cures, diagnoses, heals, or prevents any condition in humans.
Reported dose ranges in research models
Published preclinical and clinical research articles describe semaglutide and retatrutide at sub-milligram weekly ranges, with retatrutide ranges often appearing higher in dose-escalation summaries. Investigators select dose ranges based on the receptor pharmacology and the specific model being studied. Amino Fuel Labs does not publish suggested human dosing and does not provide dose conversion guidance for any compound listed on this site.
Quality, identity, and purity documentation
Both research peptides are released only after third-party HPLC verification. The Certificate of Analysis lists peptide identity, lot number, manufacture and retest dates, appearance, and measured purity. Lot numbers on the vial match lot numbers on the COA so investigators can confirm that the documentation corresponds to the physical sample they received.
Choosing between them for a research workflow
Selection between retatrutide and semaglutide in a research context typically follows the receptor question the investigator is asking. A single-agonist GLP-1 question points to semaglutide; a multi-receptor metabolic question points to retatrutide. Both are lyophilized, stored per COA guidance, and used strictly for laboratory research. Amino Fuel Labs does not make therapeutic claims about either compound.